<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03862833</url>
  </required_header>
  <id_info>
    <org_study_id>RC18_0419</org_study_id>
    <nct_id>NCT03862833</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant</brief_title>
  <acronym>HILDEGAZ</acronym>
  <official_title>Phase 1 Dose Escalation of Early Infusion of Zoledronic Acid in Combination With Increasing Low-dose of Interleukin-2 in Order to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allogeneic Stem Cell Transplantation (SCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients receiving haplo-SCT are at high-risk of relapse. Vγ9Vδ2 T cells exhibit is a&#xD;
      well-known population able to exert cytotoxicity toward a large range of tumor in vitro or in&#xD;
      vivo. Activating and expanding Vγ9Vδ2 T cells early after haplo-SCT by using a combination of&#xD;
      Zoledronic acid and low-dose interleukine (IL) -2 may be of benefit for patients by reducing&#xD;
      incidence of relapse. The optimal dose of IL-2 to use remains to be determined.&#xD;
&#xD;
      This will be a Phase 1 3+3 escalation study. Three to 15 patients are planned. It will be&#xD;
      proposed to Patients who refuse to participate to have samples collected until day +70 to&#xD;
      study immune and gamma/delta T cells reconstitutions after haplo-transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Zoledronic acid will be administered as a single dose according to marketing and regulatory&#xD;
      authorization at the dose of 4 mg over 15 min intravenously at day+15 post-transplant.&#xD;
      Zoledronic acid infusion must be stopped in case of grade 3/4 adverse events during infusion.&#xD;
&#xD;
      IL-2 will be administered at a unique low-dose level 5 days per week for 4 consecutive weeks&#xD;
      from Monday to Friday subcutaneously . IL-2 has already marketing authorization for various&#xD;
      indications.&#xD;
&#xD;
      Three IL2 levels will be tested:&#xD;
&#xD;
      Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions&#xD;
      UI/Infusion Zoledronic acid and IL2 have to start at day+15 if it is a Monday or the first&#xD;
      Monday following day+15 in order to avoid administration on week-end.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a group of patient will received IL2+ zoledronic acid a group of patient will not received IL2+ zoledronic acid</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine the maximum tolerated dose (MTD) of early administration of increasing doses of low-dose IL-2 in combination with a fixed dose of Zoledronic acid after haplo-SCT</measure>
    <time_frame>28 days after the last injection of IL2</time_frame>
    <description>A dose-limiting toxicity (DLT) will be defined as:&#xD;
non-hematological toxicity of grade 4, including grade 4 acute GVHD 4.&#xD;
non-hematological toxicity of grade 3 non-reversible for &gt; 7 days or reappearance of the same grade 3 after reintroduction of IL2 in case of return to at least one grade 1.&#xD;
an acute GVHD grade 2-3 for &gt; 7 days or reappearance of GVHD grade 2-3 acute GVHD after reintroduction of IL2 if at least grade 1 acute GVHD is restored.&#xD;
a reappearance of a grade 3/4 IL2 allergic reaction after reintroduction of IL2 in the event of a return to at least grade 1 after the occurrence of an allergic reaction of grade 3/4 IL2 when of the administration.&#xD;
grade 4 pancytopenia with hypocellular bone marrow (no disease detection) for &gt; 4 weeks after the last administration of IL2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>day 30, 60,90/100, 6 months and 1 year post-transplant</time_frame>
    <description>Concentration of sustained neutrophil recovery (&gt;500 Giga/L) with full or mixed donor chimerism documentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism (mixed, full or uncompleted)</measure>
    <time_frame>day 30, 60,90/100, 6 months and 1 year post-transplant</time_frame>
    <description>Evaluation of CD3+ T-cell chimerism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>last patient follow up : 36 months</time_frame>
    <description>the time from day 0 of allo-SCT to death or last follow-up for surviving patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>last patient follow up : 36 months</time_frame>
    <description>time from day 0 of allo-SCT to time without evidence of relapse or disease progression censored at the date of death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
    <time_frame>last patient follow up : 36 months</time_frame>
    <description>any event related to re-occurrence of the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non relapse mortality</measure>
    <time_frame>day 100 post transplant and one year post-transplant</time_frame>
    <description>death from any cause without previous relapse or progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GVHD</measure>
    <time_frame>day 100 post transplant one year post-transplant</time_frame>
    <description>Acute GVHD: Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016 Jan;22(1):4-10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic and immune reconstitutions post-transplant</measure>
    <time_frame>before the graft and at days 15, 22, 29, 36, 45, 70</time_frame>
    <description>median time for neutrophils recovery (first day with &gt;0.5 Giga/L for three consecutive days) and platelets recovery &gt;20, 50 and 100 Giga/L; T CD3, CD4, CD8, NK, B, Tregs, g/d T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR) rate for lymphoma patients</measure>
    <time_frame>day 100 post transplant</time_frame>
    <description>Cheson criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>g/d T cells detection after haplo-SCT</measure>
    <time_frame>before the graft and at days 15, 22, 29, 36, 45, 70</time_frame>
    <description>Evaluation of T CD3, CD4, CD8, NK, B, Tregs, g/d T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perturbation of ionic metabolism</measure>
    <time_frame>before the graft and at days 15, 22, 29, 36, 45, 70</time_frame>
    <description>Evaluation of Vitamin D, Ca, Ph, Na, K, serum creatinine, bilirubin (direct and total), alkaline phosphatase, gammaGT, ALAT, ASAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of dysthyroid disease</measure>
    <time_frame>before the graft and at day 70</time_frame>
    <description>Dosage of T3 T4 TSH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic GVHD</measure>
    <time_frame>one year post-transplant</time_frame>
    <description>Chronic GVHD: Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zoledronic acid and IL-2 Zoledronic acid: 4 mg&#xD;
Three IL2 levels will be tested:&#xD;
Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no experimental treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL2</intervention_name>
    <description>Three IL2 levels will be tested:&#xD;
Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>4 mg at day +15 post graft</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-70 years old&#xD;
&#xD;
          -  Patients with a hematological disease eligible for a haplo-SCT using the Baltimore&#xD;
             regimen as conditioning regimen (Luznik, BBMT, 2008) (See 5.1.2)&#xD;
&#xD;
          -  Patients with no HLA matched sibling or unrelated donors&#xD;
&#xD;
          -  ECOG &lt;=2&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patient affiliated to or beneficiary of the National Health Service&#xD;
&#xD;
          -  Patients previously transplanted are eligible to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a HLA matched sibling or unrelated donor&#xD;
&#xD;
          -  Active uncontrolled infections&#xD;
&#xD;
          -  HIV positive, active Hepatitis B or C&#xD;
&#xD;
          -  Childbearing or child-breastfeading women&#xD;
&#xD;
          -  Women or men without effective contraceptive barrier if needed&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50% with no previous severe cardiopathy&#xD;
&#xD;
          -  Respiratory insufficiency defined as DLCO &lt;40% of the corrected value&#xD;
&#xD;
          -  Creatinine clearance &lt;50 ml/min&#xD;
&#xD;
          -  Serum bilirubin &gt;2.5 or transaminases &gt;5 fold of normal value except if due to the&#xD;
             hematological disease&#xD;
&#xD;
          -  Previous or concurrent second malignancy except for adequately treated basal cell&#xD;
             carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively&#xD;
             treated solid cancer, with no evidence of disease for at least 2 years&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  Participation at the same time in another study in which investigational drugs are&#xD;
             used&#xD;
&#xD;
          -  Absence of written informed consent&#xD;
&#xD;
          -  Contra-indication to Zoledronic acid: known hypersensitivity to Zoledronic acid or&#xD;
             other bisphosphonate or Zoledronic acid formulation (excipients)&#xD;
&#xD;
          -  Recent or programmed dental care&#xD;
&#xD;
          -  Contra-indication to IL-2: known hypersensitivity to IL-2 or IL-2 formulation&#xD;
             (excipients)&#xD;
&#xD;
          -  No previous ou current use of zoledronic acid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>patrice chevalier, MD-PHD</last_name>
    <phone>+33 2 40 08 39 94</phone>
    <email>patrice.chevallier@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nantes Uh</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice CHEVALLIER, MD-PHD</last_name>
      <email>patrice.chevallier@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice CHEVALLIER, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haplo-SCT</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Zoledronic acid</keyword>
  <keyword>IL-2</keyword>
  <keyword>g/d T cells</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

